Ovagen — Khavinson bioregulator — liver / gastrointestinal (CRITICAL: zero published human trials)
Ovagen (Glu-Asp-Leu) is marketed as a liver and gastrointestinal bioregulator. The EDL tripeptide does show bioactivity in vitro (HIV protease inhibition confirmed). HOWEVER: ZERO published peer-reviewed human clinical trials exist for Ovagen's marketed liver/GI/ovarian effects. All promotional claims cite an unverifiable '106-patient study' with no journal citation, author list, or accessible publication. PubMed search returns zero results for Ovagen human studies.
نظرة عامة
هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.
فئة المركّب
Khavinson bioregulator — liver / gastrointestinal (CRITICAL: zero published human trials)
آلية العمل
Ovagen (Glu-Asp-Leu) is marketed as a liver and gastrointestinal bioregulator. The EDL tripeptide does show bioactivity in vitro (HIV protease inhibition confirmed). HOWEVER: ZERO published peer-reviewed human clinical trials exist for Ovagen's marketed liver/GI/ovarian effects. All promotional claims cite an unverifiable '106-patient study' with no journal citation, author list, or accessible publication. PubMed search returns zero results for Ovagen human studies.
الوضع التنظيمي
Not FDA approved. Supplement/research peptide. High conflict of interest: developed and sold by the same institution (Institute of Bioregulation and Gerontology).
مستوى الأدلة
INSUFFICIENT — Zero published peer-reviewed human clinical trials. In vitro EDL tripeptide bioactivity confirmed but no human data for marketed indications. Evidence score: 1/5.